At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparing the Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas on Urinary Albumin Excretion in People With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Dipeptidyl Peptidase 4 Inhibitor and Sulfonylurea for Type 2 Diabetes Mellitus and Proteinuria. Completed, enrolled 101 participants.
Detailed Summary
Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the treatment of type 2 diabetes mellitus (T2DM). Although both medications effectively lower plasma glucose levels, differences may exist in their pharmacokinetics and effect on the kidney. In the context of diabetic kidney disease, DPP-4 inhibitors may confer renal protection through several putative mechanisms. In contrast, sulfonylureas are associated with weight gain and cardiac dysfunction, which may adversely influence kidney function. The investigators hypothesize that DPP-4 inhibitors and sulfonylureas may have a different effect on the diabetic kidney. This study compares the effect of DPP-4 inhibitors and sulfonylureas on urinary albumin excretion in patients with newly diagnosed T2DM.
Study Details
Timeline
Interventions
Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily